Professional Documents
Culture Documents
PRO Panorama
Your midday briefing from Moneycontrol Pro
Dear Reader
In the latest addi on to Moneycontrol Pro, we bring you a daily offering that will hit your inbox, Pro
Panorama. This will give you an overview of what has been served on the Moneycontrol Pro pla er on
that day. You can click through and read the ar cles from the convenience of your inbox. Of course, if you
prefer reading them directly on the app you have the op on to unsubscribe from this email.
If I had been wri ng this newsle er a few hours earlier, I would have been exultant at the 3.8percent
rally in domes c equi es, on top of a 9percent gain yesterday. But the picture has changed at the me of
wri ng, with the market giving up all its gains and now is down marginally. Where it ends is anybody’s
guess and nowadays, even the brave may not venture down that path.
All of us know that the real ques on we are all wai ng for is when this lockdown will be li ed and what
happens next. The economy is wai ng and ‘How soon will the economy recover a er the lockdown
ends?’ is an ar cle you should read to find answers to those ques ons. Read here.
A related issue is the support that state governments need to fight the a er effects of the pandemic.
Tweaking the FRBM Act to allow higher borrowings and front-loading alloca on of central funds are the
need of the hour, we say. Read more.
There is some good news headed our way, if we are able to control the virus, as the MSCI rebalancing
suggests money may be headed our way. Read more. While this is good news, NBFCs seem to be
wearing a big sulk as they seem to have been le out in the RBI package. If banks don’t allow NBFCs
forbearance on their loans then how will NBFCs give their borrowers a relaxa on? Read more.
Our hard-working team of independent research analysts have put together these reports for you:
1 of 2 08-04-2020, 15:13
Gmail - Dead cat bounce https://mail.google.com/mail/u/0?ik=88487e837a&view=pt&search=all...
COVID-19: Which pharma companies can benefit from the export ban relaxa on?
For some pharma products, a spike in demand is an cipated and could remain elevated for some me to
come. Read more.
Our team of technical analysts have put together these recommenda ons: Ni y, Godrej Consumer,
L&T Finance and Tata Motors.
Thank you for subscribing to Moneycontrol Pro. We would love to hear from you. For any feedback on the
product and sugges ons please click here. We promise to read your responses although we might not be
able to reply to each one individually.
Ravi Ananthanarayanan
Sent by Moneycontrol
Shri Ram Mills Ganpat Rao Kadam Marg, Worli
Mumbai Maharashtra 400018
India
2 of 2 08-04-2020, 15:13